# VA Partnership to Increase Access to Lung Screening

## Drew Moghanaki, MD, MPH

Service Chief, Radiation Oncology Atlanta Veterans Affairs Health Care System

Principal Investigator: VA-PALS





U.S. Department of Veterans Affairs





# The Mystery of VA









# VA Demonstration Project (2012-15)





**Robert Petzel, Under Secretary for Health** VHA – Central Office Resigned 2014

Linda Kinsinger, MD, MPH VHA Chief Consultant for Preventive Services (NCP) Retired 2015



Charles Anderson, MD, PhD VHA Chief Consultant Diagnostic Services Retired 2016

#### JAMA Internal Medicine | Original Investigation

# Implementation of Lung Cancer Screening in the Veterans Health Administration

Linda S. Kinsinger, MD, MPH; Charles Anderson, MD, PhD; Jane Kim, MD, MPH; Martha Larson, BSN, MS; Stephanie H. Chan, MPH; Heather A. King, PhD; Kathryn L. Rice, MD; Christopher G. Slatore, MD, MS; Nichole T. Tanner, MD, MSCR; Kathleen Pittman, BSN, MPH; Robert J. Monte, MBA; Rebecca B. McNeil, PhD; Janet M. Grubber, MSPH; Michael J. Kelley, MD; Dawn Provenzale, MD, MSc; Santanu K. Datta, PhD; Nina S. Sperber, PhD; Lottie K. Barnes, MPH; David H. Abbott, MS; Kellie J. Sims, PhD, MS; Richard L. Whitley, BS; R. Ryanne Wu, MD, MHS; George L. Jackson, PhD, MHA

#### Evaluation of the VA Lung Cancer Screening Clinical Demonstration Project

#### Prepared for:

Department of Veterans Affairs, Office of the Under Secretary for Health

#### Prepared by:

- 1-Health Services Research & Development Center of Innovation, Durham Veterans Affairs Medical Center
- 2- National Center for Health Promotion and Disease Prevention, Office of Patient Care Services
- 3- National Radiology Program Office, Diagnostic Services, Office of Patient Care Services
- 4- Veterans Engineering Resource Center, Pittsburgh Veterans Affairs Medical Center

#### **Report Authors:**

George L. Jackson, PhD, MHA<sup>1</sup> Heather A. King, PhD<sup>1</sup> Rebecca B. McNeil, PhD<sup>1</sup> Janet M. Grubber, MSPH<sup>1</sup> Dawn Provenzale, MD, MSc<sup>1</sup> Santanu K. Datta, PhD<sup>1</sup> Nina S. Sperber, PhD<sup>1</sup> Charles Anderson, MD, PhD<sup>3</sup> Martha Larson, BSN, MS<sup>2</sup> Lottie K. Barnes, MPH, CHES<sup>1</sup> Robert J. Monte, RPh, MBA<sup>4</sup>

Report Date: March 2016 Howard C. Bachtel<sup>4</sup> Kathleen S. Pittman, RN, MPH<sup>2</sup> David H. Abbott, MS<sup>1</sup> Kellie J. Sims, PhD<sup>1</sup> Richard L. Whitley<sup>1</sup> R. Ryanne Wu, MD, MHS<sup>1</sup> Jane A. Kim, MD, MPH<sup>2</sup> Stephanie H. Chan, MPH<sup>2</sup> Heidi L. Martin, BSN, MA<sup>2</sup> Linda S. Kinsinger, MD, MPH<sup>2</sup>

#### **CHALLENGES**

- 1. Approx 2/3 = abnormal finding
- 2. Tracking = complex
- 3. Coordination of care = variable

#### **NEEDS**


- 1. System-wide tracking registry
- 2. Radiologists, CT scanners, staff
- 3. Training for primary care
- 4. Engaging pulmonology & oncology

#### Table 1. VA Patient Population for Screening

Patients:	%	VA population
	Advancing	
Potentially eligible for LDCT		
		2,780,933
Eligible for LDCT	32.0%	545,063
Qualifying for LDCT; met all criteria	84.3%	494,372
Patients Agree to LCS; Minneapolis excluded	55.5%	274,376
Completed LDCT; included in Eval. Anal.	85.9%	235,689
Positive (Nodules needed tracking + possible	51.7%	121,851
Lung Ca + doc. Lung Ca)		
Possible Lung Ca	1.50%	3,535
Documented Lung Ca	1.60%	3,771
Negative	48.3%	113,838
Incidental Finding Requiring Follow-up	32.4%	76,363

> 4mm

# Why We Can't Sit Still



## Department of Veterans Affairs

# Memorandum

Date: NOV 2 7 2017

From: Deputy Under Secretary for Health for Operations and Management (10N)

- Subj: Lung Cancer Screening with Low Dose Computed Tomography (VAIQ: 7845332)
- To: Network Director (10N1-23) VISN Chief Medical Officers (10N1-23)
- Thru: Assistant Deputy Under Secretary for Health for Clinical Operations (10NC) Executive Director, Primary Care Operations (10NC3) Chief Consultant for Preventive Medicine (10P4N) Chief Consultant for Diagnostic Services (10P11D)



# **Co-Principal Investigators**





**Claudia Henschke, PhD, MD** Mt Sinai Medical School, NY **Rick Avila, MS** Paraxial



## Paraxial Technologies













## Bristol-Myers Squibb Foundation

# VHA Support and Guidance

## Central Office

- Office of Strategic Partnerships
- Diffusion of Excellence
- Office of Rural Health
- Center for Innovation


## **National Programs**

- Diagnostic Services
- Office of Information & Technology
- Health Promotion & Prevention (NCP)
- Oncology
- Radiation Oncology
- Quality Enhancement Research Initiative





## I-ELCAP – Lung Screening Sites



# Project Goals Funded through FY20

#### 1) VAPALS-IELCAP Software Management System

• VistA-based – open source

### 2) Implement Best Practices at 10 VAMCs

- Structured reporting (LungRADS or I-ELCAP protocols)
- LDCT phantoms (Accumetra)


## 3) Centralized Training and QA


- Navigator training
- Radiology training (dual reads, on-site in-services)


### 4) Evaluate Implementation, Analyze Outcomes


• Present to VA leadership (Quality, Operations, Policy)













Patient Lookup					
Patient					
gl					
Gaylord304,Halie8	379				
Last 5: G5844	DOB: 11/01/1934	Gender: MALE			
Gaylord519,Trent1	21		)		
Last 5: G6762	DOB: 03/30/1963	Gender: MALE			
Gaylord674,Joyce	307				
Last 5: G9329	DOB: 09/22/1963	Gender: FEMALE	VAPALS- ELCAP		
Gerhold141,Ora75	i				
Last 5: G2939	DOB: 02/09/1957	Gender: MALE			
Gerhold486,Dixie7	37				
Last 5: G6598	DOB: 04/18/1952	Gender: MALE	🚳 VAPALS- ELCAP		
Gerhold486,Eino9	21				
Last 5: G9949	DOB: 02/09/1997	Gender: FEMALE	VAPALS- ELCAP		
Gerhold521,Roger	rs573				
Last 5: G1285	DOB: 07/03/1962	Gender: FEMALE			
Gerhold697,Nicole915					
Last 5: G3007	DOB: 09/02/1952	Gender: MALE			



#### Intake but no CT Evaluation

Enrollment Date	Name	SSN	Followup
5/23/2018	Dibbert829,Bethany196	999-11-2141	baseline
5/24/2018	Toy38,Laverne139	999-68-1215	baseline
6/11/2018	Adams529, Christop677	999-23-4212	baseline
6/12/2018	Effertz802,Caleb131	999-83-3568	baseline
6/14/2018	Abernathy614,Donavon721	999-98-9135	baseline
6/15/2018	Schaefer749,Nicolette831	999-92-6912	baseline
6/27/2018	Auer171,Eliezer702	999-67-1413	baseline
6/28/2018	Nikolaus949,Tobin128	999-75-8602	baseline
8/1/2018	Keebler293,Malinda715	999-34-4835	baseline
8/9/2018	Feeney725,Madilyn343	999-54-3455	baseline
8/10/2018	Altenwerth668, Darius 875	999-75-8849	baseline
8/21/2018	Pfeffer335,Jason584	999-64-7860	baseline



#### Gaylord304, Halie879 999-46-5844 DOB: 11/1/1934 AGE: 84 GENDER: M

#### **CT Evaluation Form**

Scan	Nodules	Emphysema/Coronary	Calcifications	Other Abnormalities	Impression & Follow Up
Seen	informa	tion			
Scan	Informa	llion			
* CT stud	y date				
12/10/2	018	<b>***</b>			
MM/DD/YY	YY				
Signing ra	adiologist		* Radiologist	t	
		\$			
Clinical ir	formation				
					/
	e in impressio	n			
	n performed	at outside institution			

CT Evaluation Form × +		
$\leftarrow$ $\rightarrow$ C $\triangle$ (i) Not Secure   de	lemo.va-pals.org:9080/vapals	☆ 🖾 🗉 🎯 🍪 😆   🚳 🗿
VA Citrix Access VCU Pubmed	📄 Journals 🚾 VCU ESS 🚾 VCU Libraries 🔞 Connect VCU Hea 🄟 Forest Hill Park M 🚾 VCU Time C	Off Req C Postop Nomogram »
Scan Nodules Emphysema/Con	pronary Calcifications Other Abnormalities Impression & Follow Up	
+ Add nodule		
Nodule ID	Nodule 1	
* Is it new? ⑦	- +	
* Endobronchial? ⑦	- \$	
* Most likely location? ⑦	- \$	
* Nodule seen in series ⑦		
* Nodule seen in images ⑦		
* Nodule status ?	- \$	
* Nodule consistency ⑦	- \$	
* Length (mm) ⑦		
* Maximum width (mm) 🕐		
Mean diameter (mm) 🕐	-	
Height (mm)		
Volume (mm <sup>3</sup> )	Calculate	
* Solid comp. of part-solid	lenati x width	

CT Evaluation Form × +		
$\leftarrow$ $\rightarrow$ C $\triangle$ (i) Not Secure   dem	no.va-pals.org:9080/vapals	☆ 🖾 💩 ⊗ 😵 関 💽
🔂 VA Citrix Access vcu VCU Pubmed 🛅 .	Journals 🚾 VCU ESS 🚾 VCU Libraries 🕲 Connect VCU Hea 🔟 Forest Hill Park N	M vcu VCU Time Off Req 💽 Postop Nomogram »
Scan Nodules Emphysema/Coro	onary Calcifications Other Abnormalities Impression & Follow Up	
* Solid comp. of part-solid	lengtł x width	
Solid mean diameter(mm) ⑦	-	
Smooth edges ?	Yes	
Calcifications	Yes	
Index Nodule ⑦		
Spiculated	Yes	
Distance from the costal pleura (mm)? ③		
Action ⑦	- \$	
Comment ⑦		
Pathologic diagnosis ⑦ + Add nodule	-For Pathology Use Only-	

Additional non-calcified nodules

CT Evaluation Form × +						
$\leftarrow$ $\rightarrow$ C $\triangle$ (i) Not Secure   demo.va-pals.org:9	80/vapals			\$		÷   👰 O
🔂 VA Citrix Access 🚾 VCU Pubmed 🛅 Journals 🚾 VCU	ESS vcu VCU Libraries 🔘	Connect VCU Hea	Forest Hill Park M	vcu VCU Time Off Req	Postop Nomogram	»
Scan Nodules Emphysema/Coronary Calcification	Other Abnormalities	Impression & Follow	v Up			
Impression						
Annual repeat and follow-up CT scans should utilize the sa	me low-dose protocol used fo	or baseline low-dose	CT scans.			
* Nodules						
No evidence of nodules. Follow-up as recommended.						
Nodule(s) as described. Consistent with old granulomatou	s disease. Follow-up as recorr	nmended.				
Nodule(s) unchanged, as described. Follow-up as recommended in the second se	ended.					
Nodule(s) as described. Follow-up as recommended.						
Other Findings						
O No other significant abnormalities.						
Other abnormalities and suggested follow-up as described	above.					
Impression remarks						
						li

CT Evaluation Form × +		
$\leftarrow \rightarrow$ C $\bigtriangleup$ (i) Not Secure   demo.va-pals.org:9080/	vapals	Sharing Screenshot A link to your screenshot was copied to your
🔒 VA Citrix Access 🚾 VCU Pubmed 🛅 Journals 🚾 VCU ESS	5 vcv VCU Libraries 🔘 Connect VCU Hea 🔟 Forest Hill Park M vcv VCU Tir	clipboard.
Scan Nodules Emphysema/Coronary Calcifications	Other Abnormalities Impression & Follow Up	
Follow Up select one or more		
CT follow up:		
Annual repeat Now 1 month 3 months	6 months Other	
Approximate follow-up date:		
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )		
MM/DD/YYYY		
Other follow up:		
Antibiotics Diagnostic CT PET Percutaneou	s biopsy 🛛 Bronchoscpy 💭 Pulmonary consultation 🗌 Refer to tumor b	board O No other further follow-up Other
* Specify		
specify		
Lung-RADS		
* Category	Modifiers	
Not applicable	S - clinically significant or potentially clinically significant findings (non lung c	ancer)
O (incomplete)	C - prior diagnosis of lung cancer who return to screening	
1 (negative)		
2 (benign appearance or behavior)		
3 (probably benign)		
4A (suspicious)		
○ 4B (suspicious)		

4X (suspicious)

COMPUTED TOMOGRAPHY



## CT screening for lung cancer: comparison of three baseline screening protocols

Claudia I. Henschke  $^{1,2,3}$   $\odot \cdot$  Rowena Yip  $^{1} \cdot$  Teng Ma  $^{1,4} \cdot$  Samuel M. Aguayo  $^{2} \cdot$  Javier Zulueta  $^{5} \cdot$  David F. Yankelevitz  $^{1} \cdot$  Writing Committee for the I-ELCAP Investigators

